Health Tech Capitol | Arrowhead Pharmaceuticals notches $25 million milestone payment
16749
post-template-default,single,single-post,postid-16749,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Arrowhead Pharmaceuticals notches $25 million milestone payment

04 May Arrowhead Pharmaceuticals notches $25 million milestone payment

Posted at 09:06h in Uncategorized by
0 Likes

Arrowhead Pharmaceuticals is getting a $25 million milestone payment from Janssen Pharmaceuticals, and the payment is coming sooner than expected.

Arrowhead is headquartered in Pasadena, California, but its main employment base is in Madison, at 502 S. Rosa Road. The firm has begun administering doses of its chronic hepatitis B drug to patients in a trial that’s been tweaked.

The new study looks at how Arrowhead’s JNJ-3989 — formerly known as ARO-HBV — works in combination with two other drugs chosen by Janssen but not publicly identified.

Read more at the Wisconsin State Journal 

No Comments

Sorry, the comment form is closed at this time.